PolyPid (PYPD) director details vested and future stock options
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
PolyPid Ltd. director Robert Benjamin Stein reported his existing holdings of stock options to purchase Ordinary Shares. These options cover individual blocks such as 312 shares at an exercise price of 11.4000 per share expiring on 2033-05-05 and 6,500 shares at 4.2400 per share expiring on 2034-07-02. Another grant for 14,440 underlying shares has an exercise price of 2.6700 per share and expires on 2035-06-25, with vesting on a quarterly basis through 2029. Several earlier grants are already fully vested, reflecting established equity-based compensation rather than new market transactions.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Stein Robert Benjamin
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
| holding | Stock option (right to buy) | -- | -- | -- |
Holdings After Transaction:
Stock option (right to buy) — 312 shares (Direct)
Footnotes (1)
- The options were granted on May 5, 2023 and fully vested as of May 5, 2024. The options were granted on June 18, 2020 and fully vested as of June 4, 2023. The options were granted on April 13, 2021 and fully vested as of April 13, 2022. The options were granted on May 3, 2022 and fully vested as of May 3, 2023. The options were granted on July 2, 2024 and fully vested as of July 2, 2025. The options were granted on June 25, 2025 and vest on a quarterly basis beginning May 12, 2025 until May 12, 2029.
Key Figures
Option grant: 312 underlying shares at 11.4000
Option grant: 6,500 underlying shares at 4.2400
Option grant: 14,440 underlying shares at 2.6700
3 metrics
Option grant
312 underlying shares at 11.4000
Stock option expiring 2033-05-05, fully vested by 2024-05-05
Option grant
6,500 underlying shares at 4.2400
Stock option expiring 2034-07-02, fully vested by 2025-07-02
Option grant
14,440 underlying shares at 2.6700
Grant dated 2025-06-25, expires 2035-06-25, vests quarterly to 2029-05-12
Key Terms
Stock option (right to buy), Ordinary Shares, fully vested, vest on a quarterly basis
4 terms
Stock option (right to buy) financial
"security_title: Stock option (right to buy)"
fully vested financial
"The options were granted on May 5, 2023 and fully vested as of May 5, 2024."
vest on a quarterly basis financial
"The options were granted on June 25, 2025 and vest on a quarterly basis"
FAQ
What does PolyPid (PYPD) director Robert Benjamin Stein report in this Form 3?
Robert Benjamin Stein reports his existing holdings of stock options to purchase PolyPid Ordinary Shares. The filing lists multiple option grants with specific exercise prices, share amounts, vesting schedules, and expiration dates, showing his current equity-based compensation position rather than new trades.
What are some key exercise prices on Robert Benjamin Stein’s PolyPid (PYPD) options?
Stein’s options include exercise prices of 11.4000, 23.0700, 4.2400 and 2.6700 per underlying Ordinary Share. Each exercise price is tied to a specific grant, share amount, and expiration date, illustrating a range of potential purchase costs over time.
When do Robert Benjamin Stein’s PolyPid (PYPD) stock options expire?
Stein’s reported option grants have expiration dates spanning from 2030-06-18 through 2035-06-25. For example, one 312-share grant expires on 2033-05-05, while the 14,440-share grant with a 2.6700 exercise price expires on 2035-06-25.
Are Robert Benjamin Stein’s PolyPid (PYPD) stock options already vested?
Several grants are fully vested, including options granted on May 5, 2023, June 18, 2020, April 13, 2021, May 3, 2022, and July 2, 2024. Another grant dated June 25, 2025 for 14,440 shares vests quarterly from May 12, 2025 until May 12, 2029.